review_heavy
Review literature is very dense relative to primary central evidence.
fulltopmoderate inflation risk
Alpha diversity
crohn's disease
Alpha diversity looks like a credible signal in crohn's disease, though some caution is still warranted.
Alpha diversity shows a strong literature footprint in crohn's disease, with substantial central evidence and broader supporting literature.
alpha_diversity
Credibility score
100
Human translation
3/5
Reproducibility
5/5
Novelty
1/5
Actionability
5/5
Credibility 100Human translation 3/5Reproducibility 5/5Novelty 1/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- retrieval noise or disease-specificity issues may remain
Internal review flags
1 flagsPrimary central evidence
31 papersMucosa-Associated Ileal Microbiota in New-Onset Pediatric Crohn's Disease.
2016Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Factors Associated with Postoperative Crohn's Disease Recurrence.
2017Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The microbiome of Crohn's disease aphthous ulcers.
2018Gut pathogens
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome.
2019PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.
2019World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile.
2019United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Gut Microbial Profile of Preclinical Crohn's Disease Is Similar to That of Healthy Controls.
2020Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Altered Skin and Gut Microbiome in Hidradenitis Suppurativa.
2022The Journal of investigative dermatology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes.
2021Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A Microbial Signature for Paediatric Perianal Crohn's Disease.
2022Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.
2022Microbiology spectrum
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metagenomic assembled plasmids of the human microbiome vary across disease cohorts.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intercontinental Gut Microbiome Variances in IBD.
2022International journal of molecular sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
2023Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota analysis for prediction of clinical relapse in Crohn's disease.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection.
2023Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Development of the intestinal microbiome in cystic fibrosis in early life.
2023mSphere
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
CRP in Outpatients with Inflammatory Bowel Disease Is Linked to the Blood Microbiota.
2023International journal of molecular sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Deciphering salivary microbiome signature in Crohn's disease patients with different factors contributing to dysbiosis.
2023Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Altered Bile Acid and Pouch Microbiota Composition in Patients With Chronic Pouchitis.
2024Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota signatures in inflammatory bowel disease.
2024United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?
2024Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Core microbiome-associated proteins associated with ulcerative colitis interact with cytokines for synergistic or antagonistic effects on gut bacteria.
2024The ISME journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease.
2024Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research.
2025EBioMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome shifts in adolescents after sleeve gastrectomy with increased oral-associated taxa and pro-inflammatory potential.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characterization of the salivary microbiome of adults with inflammatory bowel disease.
2025Journal of oral microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial.
2025Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease.
2026Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Decoding IBD progression: a dynamic biomarker atlas for personalized disease stratification.
2025Journal of translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
1 papersLinkage analysis identifies novel genetic modifiers of microbiome traits in families with inflammatory bowel disease.
2022Gut microbes
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
20 papersFarnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
2011Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
2017Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
2020Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice.
2020Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner.
2020Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Angiogenin maintains gut microbe homeostasis by balancing α-Proteobacteria and Lachnospiraceae.
2021Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota.
2021Autophagy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling.
2021Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota-mediated lysophosphatidylcholine generation promotes colitis in intestinal epithelium-specific Fut2 deficiency.
2021Journal of biomedical science
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Comparative analysis of gut microbiota in healthy and diarrheic yaks.
2022Microbial cell factories
Disease-relevant preclinical or model-based paper useful as supporting evidence.
TNF ΔARE Pigs: A Translational Crohn's Disease Model.
2023Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis.
2023Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Enhancing recovery from gut microbiome dysbiosis and alleviating DSS-induced colitis in mice with a consortium of rare short-chain fatty acid-producing bacteria.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease.
2025Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease.
2025Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
PPARγ/β/δ Agonists Can Ameliorate Dextran Sodium Sulfate-Induced Colitis and Modulate Gut Microbiota.
2025Journal of gastroenterology and hepatology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Decreased Fecal Nicotinamide and Increased Bacterial Nicotinamidase Gene Expression in Ulcerative Colitis Patients.
2025Inflammatory bowel diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn's disease by inducing gut dysbiosis.
2025Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease.
2025Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease.
2025Journal of periodontology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
43 papersGlucocorticoid resistance in inflammatory bowel disease.
2003The Journal of endocrinology
Relevant review or meta-analysis for the signal-disease area.
Optimizing anti-TNF treatments in inflammatory bowel disease.
2014Autoimmunity reviews
Relevant review or meta-analysis for the signal-disease area.
Immunosuppressive therapies for inflammatory bowel disease.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Classical and recent advances in the treatment of inflammatory bowel diseases.
2015Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
Relevant review or meta-analysis for the signal-disease area.
Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today.
2015Journal of Crohn's & colitis
Relevant review or meta-analysis for the signal-disease area.
Practical Approaches to "Top-Down" Therapies for Crohn's Disease.
2016Current gastroenterology reports
Relevant review or meta-analysis for the signal-disease area.
Therapeutic drug monitoring in inflammatory bowel disease.
2016Current opinion in pediatrics
Relevant review or meta-analysis for the signal-disease area.
European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.
2017Journal of Crohn's & colitis
Relevant review or meta-analysis for the signal-disease area.
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
2018World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies.
2019Autoimmunity reviews
Relevant review or meta-analysis for the signal-disease area.
Maneuvering Clinical Pathways for Crohn's Disease.
2019Current gastroenterology reports
Relevant review or meta-analysis for the signal-disease area.
Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
2019Expert review of gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
Resolution of Crohn's disease.
2019Seminars in immunopathology
Relevant review or meta-analysis for the signal-disease area.
Perspective on skeletal health in inflammatory bowel disease.
2020Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Relevant review or meta-analysis for the signal-disease area.
The multiple sclerosis gut microbiota: A systematic review.
2020Multiple sclerosis and related disorders
Relevant review or meta-analysis for the signal-disease area.
Targeting T cells in inflammatory bowel disease.
2020Pharmacological research
Relevant review or meta-analysis for the signal-disease area.
The shining DIAMOND for evidence-based treatment strategies for Crohn's disease.
2020Journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Secondary causes of inflammatory bowel diseases.
2020World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
2021Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis.
2021Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review.
2022Oral diseases
Relevant review or meta-analysis for the signal-disease area.
Neurology of inflammatory bowel disease.
2021Journal of the neurological sciences
Relevant review or meta-analysis for the signal-disease area.
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
2022Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
Emerging therapeutic options in inflammatory bowel disease.
2021World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis.
2023Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia.
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Relevant review or meta-analysis for the signal-disease area.
Assessing the Relationship between the Gut Microbiota and Inflammatory Bowel Disease Therapeutics: A Systematic Review.
2023Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Non-culture-based studies of the appendiceal microbiota: a systematic review.
2023Future microbiology
Relevant review or meta-analysis for the signal-disease area.
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.
2023World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation.
2023Journal of autoimmunity
Relevant review or meta-analysis for the signal-disease area.
Helicobacter pylori and oral-gut microbiome: clinical implications.
2024Infection
Relevant review or meta-analysis for the signal-disease area.
Influence of the bile acid/microbiota axis in ileal surgery: a systematic review.
2024Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Relevant review or meta-analysis for the signal-disease area.
Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?
2024BMJ open gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
2024Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Inflammatory Bowel Diseases and the Efficacy of Probiotics as Functional Foods.
2024Frontiers in bioscience (Elite edition)
Relevant review or meta-analysis for the signal-disease area.
Saffron as a Promising Therapy for Inflammatory Bowel Disease.
2024Nutrients
Relevant review or meta-analysis for the signal-disease area.
Biological agents as attractive targets for inflammatory bowel disease therapeutics.
2025Biochimica et biophysica acta. Molecular basis of disease
Relevant review or meta-analysis for the signal-disease area.
Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
2026Gut
Relevant review or meta-analysis for the signal-disease area.
Dysbiosis of Gut Microbiota in Microscopic Colitis: Diagnostic and Therapeutic Implications.
2025Diagnostics (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
2025Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.